Hengrui Medicine (01276) obtains a notice of approval for clinical trials of drugs.

Wisdom Financial News APP, Hutchison Medicine (01276) announced that recently, Jiangsu Hutchison Medicine Co., Ltd. (hereinafter referred to as the "Company") and its subsidiaries Suzhou Shengdiya Biomedical Medicine Co., Ltd., Shanghai Hutchison Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd. received approval from the National Medical Products Administration (hereinafter referred to as the "NMPA") to conduct clinical trials for HRS-4642 Injection, SHR-1701 Injection, SHR-7367 Injection, SHR-8068 Injection, Aderbi Monoclonal Antibody Injection, Bevalzu Monoclonal Antibody Injection, Injection SHR-A2102, Famicitinib Capsules, and Hydroethanesulfonate Dalcetrapib Tablets.